Metastatic Poorly Differentiated Thyroid Cancer With Heterogeneous Distribution of 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA on PET/CT.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Apr 2021
01 Apr 2021
Historique:
pubmed:
7
11
2020
medline:
15
4
2021
entrez:
6
11
2020
Statut:
ppublish
Résumé
We present a case of a 55-year-old man with a history of poorly differentiated metastatic thyroid cancer, which is rare and shows aggressive behavior. The patient had radioactive iodine-negative multiple metastasis on 18F-FDG PET/CT, therefore 68Ga-DOTATATE and 68Ga-PSMA PET/CT were performed whether an opportunity exist for DOTATATE or PSMA-directed radionuclide therapy. Different patterns of tumoral uptakes were detected on 18F-FDG, 68Ga-DOTATATE, and 68Ga-PSMA PET/CT, as a demonstration of tumor heterogeneity.
Identifiants
pubmed: 33156050
pii: 00003072-202104000-00032
doi: 10.1097/RLU.0000000000003362
doi:
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
Organometallic Compounds
0
gallium 68 PSMA-11
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Edetic Acid
9G34HU7RV0
gallium Ga 68 dotatate
9L17Y0H71P
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e212-e213Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Lin JD, Chao TC, Hsueh C. Clinical characteristics of poorly differentiated thyroid carcinomas compared with those of classical papillary thyroid carcinomas. Clin Endocrinol (Oxf) . 2007;66:224–228.
Hiltzik D, Carlson DL, Tuttle RM, et al. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients. Cancer . 2006;106:1286–1295.
Pulcrano M, Boukheris H, Talbot M, et al. Poorly differentiated follicular thyroid carcinoma: prognostic factors and relevance of histological classification. Thyroid . 2007;17:639–646.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid . 2016;26:1–133.
Thiagarajan S, Yousuf A, Shetty R, et al. Poorly differentiated thyroid carcinoma (PDTC) characteristics and the efficacy of radioactive iodine (RAI) therapy as an adjuvant treatment in a tertiary cancer care center. Eur Arch Otorhinolaryngol . 2020;277:1807–1814.
Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate use criteria for somatostatin receptor PET imaging in neuroendocrine tumors. J Nucl Med . 2018;59:66–74.
Giovanella L, Treglia G, Iakovou I, et al. EANM practice guideline for PET/CT imaging in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging . 2020;47:61–77.
Hope TA, Abbott A, Colucci K, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177 Lu-DOTATATE. J Nucl Med . 2019;60:937–943.
Salavati A, Puranik A, Kulkarni HR, et al. Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues. Semin Nucl Med . 2016;46:215–224.
Sanli Y, Kuyumcu S, Sanli O, et al. Relationships between serum PSA levels, Gleason scores and results of 68 Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann Nucl Med . 2017;31:709–717.
Yadav MP, Ballal S, Bal C, et al. Efficacy and safety of 177 Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med . 2020;45:19–31.
Bychkov A, Vutrapongwatana U, Tepmongkol S, et al. PSMA expression by microvasculature of thyroid tumors—potential implications for PSMA theranostics. Sci Rep . 2017;7:5202.
Lengana T, Lawal IO, Mokoala K, et al. 68 Ga-PSMA: a one-stop shop in radioactive iodine refractory thyroid cancer? Nucl Med Mol Imaging . 2019;53:442–445.